Company intelligence / Profile preview

Flexipharm Austrading

Bourne End, Buckinghamshire, United Kingdom

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Flexipharm Austrading commercialises improved vial presentations and new strengths of established injectable critical care medicines for UK NHS and independent hospitals; its products, including arsenic trioxide, methylthioninium chloride and metaraminol, are fully approved and marketed in the UK as licensed or ‘specials’ medicines rather than being in clinical development.[2][8][14]

Therapeutic areas: HematologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Phebra (exclusive licence and distribution agreement for injectable critical care medicines portfolio)[2][4][14]Mawdsleys (exclusive UK wholesaler partner for distribution of products such as arsenic trioxide and methylthioninium chloride)[2][13]

Beyond the preview

Go deeper on Flexipharm Austrading.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flexipharm Austrading.

Explore the full profile